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ABSTRACT
Mesenchymal stem cells (MSCs) isolated from many tissues including bone marrow and fat can
be expanded in vitro and can differentiate into a range of different cell types such as bone, car-
tilage, and adipocytes. MSCs can also exhibit immunoregulatory properties when transplanted
but, although a number of clinical trials using MSCs are in progress, the molecular mechanisms
that control their production, proliferation, and differentiation are poorly understood. We iden-
tify MOSPD1 as a new player in this process. We generated MOSPD1-null embryonic stem cells
(ESCs) and demonstrate that they are deﬁcient in their ability to differentiate into a number of
cell lineages including osteoblasts, adipocytes, and hematopoietic progenitors. The self-renewal
capacity of MOSPD1-null ESCs was normal and they exhibited no obvious defects in early germ
layer speciﬁcation nor in epithelial to mesenchymal transition (EMT), indicating that MOSPD1
functions after these key steps in the differentiation process. Mesenchymal stem cell (MSC)-like
cells expressing CD73, CD90, and CD105 were generated from MOSPD1-null ESCs but their
growth rate was signiﬁcantly impaired implying that MOSPD1 plays a role in MSC proliferation.
Phenotypic deﬁciencies exhibited by MOSPD1-null ESCs were rescued by exogenous expression
of MOSPD1, but not MOSPD3 indicating distinct functional properties of these closely related
genes. Our in vitro studies were supported by RNA-sequencing data that conﬁrmed expression
of Mospd1 mRNA in cultured, proliferating perivascular pre-MSCs isolated from human tissue.
This study adds to the growing body of knowledge about the function of this largely uncharac-
terized protein family and introduces a new player in the control of MSC proliferation and dif-
ferentiation. STEM CELLS 2015; 00:000–000
SIGNIFICANCE STATEMENT
Mesenchymal stem cells are the subject of many clinical trials but the molecular mechanisms
involved in their production, proliferation and differentiation are poorly understood. This study
reveals that cells deficient in the MOSPD1 gene display distinct defects in mesenchymal stem
cell proliferation and differentiation suggesting an important role for this poorly characterised
gene family. Differentiation defects are rescued by expression of MOSPD1 but not MOSPD3
demonstrating that these two closely related genes are not functionally redundant.
INTRODUCTION
Mesenchymal stem cells (MSCs) hold great
promise for cell therapies because they can
be easily isolated from accessible tissues
such as bone marrow and fat and they can
be expanded extensively in vitro. They can
differentiate into bone, cartilage, and adipo-
cytes and are proposed to hold immunother-
apeutic properties upon transplantation [1].
Their use in regenerative medicine has been
widely proposed with a number of clinical
trials in progress [2, 3]. However, the molec-
ular pathways that control their production,
proliferation, and differentiation are not
clearly deﬁned.
Major sperm protein (MSP) domain-
containing proteins belong to a large family,
which are found in yeast, plants and through-
out the animal kingdom from insects to mam-
mals [4–7]. They appear to have diverse roles
in a variety of systems including nematode
reproduction, synaptic transmission in the cen-
tral nervous system in the sea slug and in the
human neurodegenerative disease amyotrophic
lateral sclerosis (ALS) [7–9]. Included in this
overarching MSP domain-containing family are
the four members of the MOSPD1 group
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(MOSPD1-4), characterized by having an N-terminal MSP
domain and a number of predicted C-terminal transmembrane
domains. Functional studies have suggested that this subfam-
ily is important during mammalian development. For example,
phenotypic characterization of a mouse strain carrying a gene
trap integration in the Mospd3 locus suggested that Mospd3
played a role in cardiac development with homozygous ani-
mals displaying a thinning of the right ventricular parietal wall
[10, 11]. More recently, the X-linked Mospd1 gene has been
implicated in the process of epithelial to mesenchymal transi-
tion (EMT), an important event involved in many developmen-
tal and tumorogenic processes [12].
To provide insight into the function of Mospd1 in develop-
ment and differentiation, we knocked out the Mospd1 gene
in mouse embryonic stem cells (ESCs) by gene targeting and
tested the ability of these MOSPD1-null cells to differentiate
into a number of different cell lineages in vitro. We noted a
deﬁciency in the differentiation of osteoblasts, adipocyte, and
hematopoietic lineages and in the proliferative capacity of
MSC-like cells. The expression proﬁle of Mospd1 mRNA in
MSCs and their precursors isolated from human tissue are
consistent with our in vitro observations. MOSPD1-null ESC
differentiation deﬁciencies were rescued by exogenous expres-
sion of Mospd1 cDNA, but not Mospd3, indicating that these
two closely related proteins have distinct functions.
MATERIALS AND METHODS
Maintenance and Self-Renewal of ESCs
All ESC lines were maintained in ESC media in the presence
of serum and leukemia inhibitory factor (LIF) as described pre-
viously [13] and were subjected to regular karyotypic analysis.
ESC self renewal assays were performed by plating 200 cells
per milliliter in ESC medium for 5 days, then stained for alka-
line phosphatase activity (Sigma-Aldrich St Louis, MO, www.
sigmaaldrich.com) to identify colonies classiﬁed as stem
(pink), mixed (pink/white), or differentiated (white) as
described previously [13].
Production of Genetically Manipulated Cell Lines
The Mospd1 targeting vector was generated by recombineer-
ing [14] using speciﬁc primers (Supporting Information Fig. S1,
Table S1). The vector contained two lox P sites ﬂanking exons
2-4 of the Mospd1 gene and an frt-neomycin-frt cassette in
the intron between exon 4 and the 30 lox P site. The full
length Mospd1 cDNA was cloned by reverse transcription
polymerase chain reaction (RT-PCR) from day 5 embryoid
bodies (EBs) using speciﬁc primers (Supporting Information
Table S1) and the Mospd1 PCR product was cut with the
restriction enzyme EcoR1 and cloned into the pCAG-IRESpuro
plasmid. Correctly orientated clones were sequenced and pro-
tein expression veriﬁed by Western blotting of transfected
COS7 cell lysates. A pCMV6-AN-GFP vector containing the
Mospd3 gene was obtained from Origene, Rockville, MD
(www.origene.com). Targeting and expression vectors were
electroporated into E14 IV (referred to as E14) mouse ESCs
using a Bio-Rad gene pulser electroporator (0.5 cm cuvette at
0.25 kV and 500 lF capacitance), plated in ESC media plus LIF
and selection was started the following day by adding 280
ng/ml G418 (concentration determined by kill curve) for 10
days. Single G418-resistant ESC colonies were picked,
expanded, and DNA isolated from each colony was screened
by Southern blot analysis. COS7 cells were transfected using
Lipofectamine 2000 (Invitrogen (Waltham, MA, www.lifetech-
nologies.com)) following manufacturer’s instructions.
Differentiation Assays
Differentiation assays are outlined in Supporting Information
Figure S2. All EB-based assays followed a similar protocol in
the initial stages where ESCs were cultured in hanging drops
(300 cells per 10 ll drop) in LIF for 2 days and resulting EBs
were harvested and cultured in suspension, in the absence of
LIF, for varying numbers of days. For cardiomyocyte differen-
tiation, EBs were cultured in suspension for 6 days, individual
EBs were plated in gelatinized wells and the presence of beat-
ing regions was scored over the following 10 days. Hemato-
poietic differentiation was carried out by culturing EBs in
suspension for 1 day in the absence of LIF (day 1 EBs) before
plating onto gelatinized plates for a further 6 days. Cells were
then dissociated and plated in methylcellulose containing
stem cell factor (SCF), erythropoietin (EPO), and interleukin 3
(IL3) as described previously [13] and colonies counted after a
further 10–15 days.
For the colony forming unit-ﬁbrobast (CFU-F) assay, day 1
EBs were plated onto gelatinized dishes and cultured for a
further 4 days before being dissociated and plated in Mesen-
cult medium (STEMCELL Technologies, Cambridge UK (www.
stemcell.com)) for 14 days then stained with Leishman stain.
Mesenchymal cells from the CFU-F assays were grown for up
to nine passages in Mesencult medium and their phenotype
conﬁrmed by ﬂow cytometry with antibodies against CD90,
CD73, and CD105.
Osteoblast differentiation was performed as described
[15] with day 1 EBs plated onto gelatinized plates for 4 days
then dissociated to single cells and 5 3 104 cells were cul-
tured in 5 ml Alpha Minimal Essential Media (MEM) (Invitro-
gen) supplemented with 15% fetal calf serum (FCS), 0.05 mM
b-mercaptoethanol, and 2 mM glutamine on gelatinized six-
well dishes for a further 14 days. At this time point, the
medium was supplemented with 50 mM b-glycerophosphate,
50 mg/ml ascorbic acid, and 1 mM dexamethasone and cul-
tured for a further 7 days. Cells were washed, ﬁxed in 70%
ethanol then stained with 10 mg/ml Alizarin Red (Sigma-
Aldrich) 12 days later (day 26).
Adipocyte differentiation was carried out by treating day
1 EBs with 1025 M retinoic acid (RA) from days 2–5 with
medium and RA being replenished at day 4. EBs were plated
onto gelatin at day 7 and treated with 5 mg/ml, 500 nM 3-iso-
butyl-1-methylxanthine (IBMX) and 400 ng/ml dexamethasone
and 5 lg/ml insulin. Medium was replenished every 2 days
until day 20 when they were stained with oil red O. For chon-
drocyte differentiation, day 5 EBs were plated in medium con-
taining 15% FCS which was replaced every 2 days until being
stained with Alcian Blue after 19 days.
Real-Time Quantitative RT-PCR
Total RNA was isolated using the RNeasy Mini kit (Qiagen,
Manchester, UK, www.qiagen.com) and 500 ng of total RNA
was reverse-transcribed using the Superscript III kit (Invitro-
gen). cDNA was subjected to quantitative RT-PCR (qRT-PCR)
using speciﬁc primers and either Roche universal library or
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TaqMan probes which were all prevalidated before use (Sup-
porting Information Table 1). The ABI 7500 FAST qPCR
machine and SDS v1.4 software (Applied Biosystems, Wal-
tham, MA [www.appliedbiosystems.com]) were used with rel-
ative quantiﬁcation being calculated using the delta delta CT
method and Hprt as an endogenous housekeeping gene.
Generation of Monoclonal Antibodies
A monoclonal a-MOSPD1 antibody was generated against the
chemically synthesized peptide MHQQKRQPELVEGNLPVFVF
(Thistle Research, Glasgow, Scotland (www.peptides.co.uk) and
Yorkshire Biosciences, York, UK (http://www.york-bio.com)).
The resulting hybridoma cells were cultured in RPMI-1640
medium (Invitrogen) supplemented with 10% heat inactivated
FCS, 2 mM L-glutamine, and 100 units penicillin–100 mg/ml
streptomycin for 2 weeks at 378C with 5% CO2 without chang-
ing the medium. This medium, containing a-MOSPD1 anti-
body, was used for subsequent immunological experiments.
Preparation and Analysis of Protein Lysates
Protein samples were prepared and analyzed by SDS PAGE
and Western blotting according to standard procedures.
Brieﬂy, cells were washed with phosphate-buffered saline
(PBS), lysed in ice-cold RIPA buffer (ThermoScientiﬁc, Wal-
tham, MA, www.thermoscientiﬁc.com), scraped from the
plate, passed through a 19G needle, washed in PBS then soni-
cated in the presence of protease inhibitors (Sigma-Aldrich).
Lysates were run on a 12% SDS/polyacrylamide electrophoresis
gel (Bio-Rad, Hercules, CA, www.bio-rad.com) then transferred
to nitrocellulose membranes by semi-dry electrotransfer. Mem-
branes were blocked for 1 hour with 5% dried milk powder in
13 TBST (25 mM Tris-HCl, pH 8.0, 125 mM sodium chloride,
0.1 % Tween 20) before hybridization with the primary anti-
bodies (1:100 a-MOSPD1 and a-MOSPD3, 1:2,000 a-GAPDH
[Abcam, Cambridge, UK, www.abcam.com]) in blocking solution
overnight at 48C. The membranes were washed in TBST and
incubated with horseradish peroxidase-conjugated secondary
antibody (1:2,000) for 1 hour at room temperature before add-
ing ECL substrate and autoradiography.
Isolation of Human MSC Progenitors from Fat Tissue
Lipoaspiration specimens used for FACS sorting, culture, and
RNA-SEQ analysis were obtained from six healthy female
donors (age range: 35–63 years; BMI range: 21.1–32.0) under-
going elective liposuction of fat from lateral axillary areas at
local plastic surgery clinics. Lipoaspirates stored overnight at
48C were washed twice with PBS lacking Ca and Mg to reduce
contamination by blood and then combined with an equal vol-
ume of Dulbecco’s modiﬁed Eagle’s medium (DMEM) medium
(Lonza, Basel, Switzerland, www.lonza.com ) containing antibi-
otics, 3.5% (w/v) bovine serum albumin (Hycult Biotech, www.
hycultbiotech.com), and 1 mg/ml collagenase (cat. #C-6685,
Sigma-Aldrich). Digestion proceeded for 40 minutes at 378C
during vigorous shaking (250 rpm) then the stromal vascular
fraction was processed as described previously [16]. Following
cell counting using a hemocytometer and trypan blue to assess
viability, the SVF was stained for 40 minutes at 378C in DMEM
medium lacking fetal bovine serum (FBS) with 2 mg/ml Hoechst
34580 (Life Technologies, Waltham, MA, www.lifetechnologies.
com), and Aldeﬂuor (StemCell Technologies) according to the
manufacturer’s instructions, to compare cytoplasmic levels of
aldehyde dehydrogenase (ALDH) in nucleated cells. The
Aldeﬂuor-stained cells, and a control containing an ALDH inhibi-
tor (ALDH-neg control), were centrifuged at 300g for 5 minutes
and resuspended in 1 ml of Aldeﬂuor assay buffer containing 2
ml of Near infrared live/dead stain (Life Technologies) and 10 ml
of FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach,
Germany, www.miltenyibiotec.com), and incubated for 10
minutes on ice. The cells were collected by centrifugation and
incubated in Aldeﬂuor assay buffer containing ﬂuorescently
labeled, anti-human, mouse monoclonal antibodies (PE- or
APC-Cy7-conjugated CD45, APC-CD34, and PE- or PerCP-Cy5.5-
conjugated CD146; BD BioSciences, San Jose, CA, www.bdbio-
sciences.com) for 20 minutes on ice to allow immunopheno-
typic staining for ﬂuoresecence activated cell sorting (FACS)
(Supporting Information Fig. S4). Cells collected by FACS were
either lysed immediately for RNA extraction or cultured for
three passages in DMEM containing antibiotics and 20% FBS. To
adjust for gene expression changes brought about by cell sort-
ing, FACS-selected cultured adventitial vascular cells (ASC) and
pericytes were stained with ﬂuorescent antibodies to CD31,
CD45, CD146, and CD34 after three passages. All cultured ASCs
were collected as they demonstrated no expression for any of
the above markers; however, only pericytes that had retained
CD146 expression in culture were isolated for RNA-SEQ
analysis.
RNA Purification and RNA Sequencing
Subpopulations consisting of freshly isolated total ASC, ALDH-
dim and -bright ASC, and ALDH-dim pericytes and their cul-
tured counterparts were sorted into cell lysis solution and
puriﬁed using the Qiagen RNeasy Micro kit (Qiagen). Total
RNA was quantiﬁed and yielded RNA integrity numbers of 7.7
or greater (2100 Agilent Bioanalyzer, www.genomics.agilent.
com). cDNA for each subpopulation was prepared using the
NuGen’s Ovation RNA-Seq System V2 kit from approximately
100 ng of RNA pooled from 2 or 3 donors and used as input
for Ovation’s Ultralow DR Multiplex System 1–8 (Nugen, San
Carlos, CA, www.nugen.com). High throughput sequencing
was conducted on an Illumina Hiseq 2000 platform to gener-
ate 100-bp paired-end reads at a depth of coverage of
approximately 79 million reads. Cluster formation achieved
approximately 86%, while the quality of reads exceeded 95%.
Fragment sequence identiﬁcation and alignment were per-
formed using TopHat and Bowtie, respectively. Samples were
normalized by RPMK (reads per kilobase of exon per million
mapped reads) which takes into account both library size and
gene length in within-sample comparisons. Similar numbers of
reads between libraries (i.e., depths of coverage) made cross-
library, individual gene comparisons possible.
Statistical Analysis
Quantiﬁable data were graphed and analyzed with the appro-
priate statistical tests (t-test or analysis of variance) using
GraphPad Prism (GraphPad Software, San Diego, CA, http://
www.graphpad.com). Analysis was performed on triplicate
data sets unless otherwise stated.
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RESULTS
Generation of MOSPD1-Null ESCs
A conditional Mospd1 targeting vector was designed with loxP
sites ﬂanking exons 2–4 of the Mospd1 gene, an frt-
neomycin-frt cassette inserted into the intron between exon 4
and the 30 loxP site with appropriate restriction enzyme sites
to differentiate between wild type, targeted ﬂoxed, and the
subsequently excised null alleles (Supporting Information Fig.
S1A). The targeting vector was electroporated into E14IV ESCs
then G418-selected colonies were isolated and analyzed to
identify ESCs carrying the correctly targeted Mospd1-ﬂoxed
allele (Mospd1tm1ﬂoxFor) (Supporting Information Fig. S1B).
Brieﬂy, genomic DNA was isolated from 179 G418-resistant
ESC clones and Spe1 and Hind111 digested DNA was assessed
by Southern blotting using probes that were 50 and 30 of the
targeting vector. We identiﬁed four ESC clones that contained
the restriction fragments diagnostic of correct targeting imply-
ing a 2% targeting efﬁciency (Supporting Information Fig.
S1B). The pCAGGS-Cre-IRESpuro plasmid [17] was electropo-
rated into a number of correctly targeted clones to excise
exons 2–4 and the frt-neo-frt cassette to produce ESCs carry-
ing the Mospd1-null allele (Mospd1tm1fFor) (Supporting Infor-
mation Fig. S1C). As Mospd1 is X-linked, targeting of the one
allele in male E14 ESCs generates a functionally null ESC line
with no Mospd1 mRNA expression. This was conﬁrmed by
quantitative RT-PCR analysis of RNA isolated from differentiat-
ing wild type and MOSPD1-null ESCs (Fig. 1A). All of the fol-
lowing functional studies were performed on two MOSPD1-
null ESC clones that were derived from independently derived
targeted ESC lines.
MOSPD1 Deficiency Has No Effect on the Maintenance
of Undifferentiated ESC
MOSPD1-null ESCs could be maintained as undifferentiated
cells in the presence of LIF in a comparable manner to control
E14 ESCs and expressed comparable levels of the stem cell
markers, Oct4 and Nanog (Fig. 1B), indicating that Mospd1
was not essential for ESC self-renewal. We conﬁrmed this in a
quantitative manner using an alkaline phosphatase clonal den-
sity assay (Fig. 1C). No signiﬁcant difference was observed in
the number of stem cell colonies formed in the presence of
LIF between control E14 and MOSPD1-null ESCs indicating
that self-renewal was not dependent on MOSPD1. A
Figure 1. Self-renewal and spontaneous differentiation of MOSPD1-null embryonic stem cells (ESCs) are comparable with control E14
ESCs. (A): Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis conﬁrmed the lack of expression of Mospd1
transcripts in differentiating day 5 embryoid bodies generated from two independently derived MOSPD1-null ESC clones compared with
control E14 (Wild type) ESCs. Data shown is the mean for the two cell lines (p < 0.001). (B): Semi-quantitative RT-PCR demonstrated
that the stem cell markers Oct4 and Nanog were expressed in two independently-derived MOSPD1-null ESCs (1 and 2) at a comparable
level to control E14 ESCs. b-Tubulin was used as a loading control. (C): The number of stem, mixed or differentiated colonies generated
from MOSPD1-null ESCs in an alkaline phosphatase clonal density assay in the presence of leukemia inhibitory factor (LIF) was not signif-
icantly different (p 5 0.4) to control E14 ESCs. (Data represent the means of two independently derived MOSPD1-null cell ESC lines).
(D): The number of stem, mixed, or differentiated colonies generated from MOSPD1-null ESCs in an alkaline phosphatase clonal density
assay in the absence of LIF was not signiﬁcantly different (p 5 0.26) to control E14 ESCs. (Data represent the means of two
independently-derived MOSPD1-null cell ESC lines).
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comparable number of differentiated and mixed colonies
were also observed indicating that MOSPD1-null cells dis-
played a similar degree of spontaneous differentiation in the
presence of LIF (Fig. 1C). When this clonal assay was per-
formed in the absence of LIF there was no signiﬁcant differ-
ence in the morphology, nor the numbers of differentiated
colonies produced between control E14 and MOSPD1-null
ESCs indicating that the early ESC differentiation events were
also Mospd1 independent (Fig. 1D). Two independently-
derived MOSPD1-null ESC clones (MOSPD1 null 1 and
MOSPD1 null 2) behaved in a similar manner and the data
shown represent the mean of the two clones.
We analyzed the expression of Mospd1 mRNA and its
close relative Mospd3 in undifferentiated ESCs and in ESCs
during EB differentiation by RT-PCR (Fig. 2A, 2B). Mospd1 is
expressed at a relatively low level in undifferentiated ESCs
(virtually undetectable by RT-PCR) and its level of expression
increases signiﬁcantly during differentiation. The closest
homologue of Mospd1 is Mospd3 and expression of this gene
was detected at a higher level in ESCs and remains at a con-
sistent level throughout the differentiation protocol (Fig. 2A).
qRT-PCR analysis conﬁrmed these ﬁndings with a signiﬁcant
increase in Mospd1 expression upon differentiation but a con-
sistent level of Mospd3 throughout the time period (Fig. 2B).
Given the sequence homology between Mospd1 and Mospd3,
we compared the expression of Mospd3 in Mospd1-null ESCs
compared with wild type ESCs throughout the differentiation
process. Although there was a slightly lower level of expres-
sion of Mospd3 in Mospd1-null ESCs compared with control
ESCs at the early stages of differentiation (days 3 and 5) these
differences were not signiﬁcant and at later stages these
minor differences were resolved (Fig. 2B). Thus we can con-
clude that the loss of Mospd1 expression is not compensated
by an upregulation of its close homologue Mospd3 and that
expression of Mospd3 is not absolutely dependent on Mospd1
(Fig. 2B).
MOSPD1-Null ESCs Can Differentiate into all Three
Germ Layers
To further characterize the effects of MOSPD1 deﬁciency, we
differentiated control E14 and MOSPD1-null ESCs in EBs in
the absence of LIF for 3 days [13] and assessed the expres-
sion of genes that were upregulated during the formation of
the three primary germ layers but were not expressed in
undifferentiated ESCs (Fig. 2C). There was no signiﬁcant differ-
ence in the expression of mesoderm (T/Bry), endoderm
Figure 2. Mospd1 expression increases during embryonic stem cell (ESC) differentiation but is not required for germline speciﬁcation
nor epithelial to mesenchymal transition (EMT). (A): Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis
of RNA isolated from undifferentiated control E14 ESCs (lanes 1 and 2) and in ESCs differentiated in the absence of leukemia inhibitory
factor (LIF) for 1, 2, 3, 4, and 5 days (lanes 3–7, respectively) and in day 12 embryoid bodies (EBs) (lanes 8 and 9) using primers comple-
mentary to Mospd1, Mospd3, and b-tubulin as a loading control. Lane 10 represents a negative control with no RNA loaded. (B): Quan-
titative RT-PCR analysis of RNA isolated from control E14 and MOSPD1-null undifferentiated ESCs (day 0) and from cells that had
differentiated in the absence of LIF for 3, 5, 7, 9, and 12 days using primers speciﬁc for Mospd1 and Mospd3. Data are expressed as
fold expression relative to the day 0 time point of each assay. (C): Quantitative RT-PCR analysis of day 3 EBs isolated from control E14
and MOSPD1-null ESCs using primers for germ lineage-speciﬁc markers, Pax6 (ectoderm), Foxa2 (endoderm), and Bry (mesoderm). (D–
F): The expression of markers associated with EMT, Cdh11 (D), Snai1 (E), and Snai2 (F) increase during the time course of differentiation
to a comparable extent in control E14 and MOSPD1-null ESCs.
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(Foxa2), or ectoderm (Pax6) markers indicating that all three
germ layers could be formed in the absence of Mospd1. A
previous study had suggested that Mospd1 played a role in
EMT [12] so we compared the expression of a number of
genes associated with EMT during the differentiation process
(Fig. 2D–2F). Snai1, Snai2, and Cdh11 were all upregulated to
a comparable extent during the differentiation of control E14
and MOSPD1-null ESCs indicating that MOSPD1 does not play
a major role in EMT in this system.
MOSPD1-Deficiency Impairs Differentiation of Some
Mesodermal Cell Lineages
We next analyzed the ability of MOSPD1-null cells to differen-
tiate into a number of mesodermal lineages using a range of
assays (summarized in Supporting Information Figs. S2, S3).
Differentiation protocols were all initiated by the formation of
EBs with the subsequent steps varying depending on the spe-
ciﬁc cell lineage to be analyzed.
Given previous reports on the role of MOSPD1 in the dif-
ferentiation of mesenchymal lineages [12], we tested the abil-
ity of MOSPD1-null cells to form colonies in medium designed
to identify mesenchymal progenitors from bone marrow,
known as CFU-F [18]. As expected, this assay identiﬁed a
number of colonies from bone marrow (Fig. 3A). We com-
pared control E14 and MOSPD1-null ESCs in this assay and
observed a signiﬁcant reduction in the production of colonies
generated from MOSPD1-null ESCs (Fig. 3A). To address
whether this assay does actually measure MSCs derived from
ESCs we further cultured cells derived from these colonies in
Mesencult medium. A population of cells expressing CD90,
CD73, and CD105 emerged from both control and MOSPD1-
null cells but cells derived from MOSPD1-null ESCs expressed
slightly lower levels of these markers than control E14 cells
(Fig. 3B–3E). We also noted that the cells that arose from the
MOSPD1-null cells took a longer time to reach conﬂuency
indicative of a reduced proliferation rate. This ﬁnding was
conﬁrmed in a quantitative manner by demonstrating that
Figure 3. MOSPD1-null cells are deﬁcient in production and proliferation of MSC-like cells. (A): The number of colony forming unit-
ﬁbrobast (CFU-F) colonies generated from MOSPD1-null embryonic stem cell (ESC) lines is signiﬁcantly lower than the number generated
from control E14 ESCs. A cell suspension isolated from mouse bone marrow was used as a positive control for the CFU-C assay. (B, C):
Flow cytometry analyses of control E14 (B) and MOSPD1-null (C) cells after nine passages in Mesencult media using antibodies against
CD90 and CD73. The proportion of cells expressing CD105 was lower on CD901/CD731 cells derived from MOSPD1- null cells compared
with control E14 cells. (D,E): The mean ﬂuorescent intensity of CD90, CD73, and CD105 staining (D) and the proportion of cells express-
ing these markers (E) was lower in higher in MOSPD1-null-derived compared with control E14-derived MSC-like cells. (F):
CD901CD731CD1051 MSC-like cells derived from MOSPD1-null ESCS proliferate at a slower rate compared with control E14 ESCs. Cells
were grown in mesencult media for a number of passages, then plated in this assay at 50,000 per square centimeter then counted 1, 3,
and 4 days later. (*, p 5 0.03) (G): Quantitative reverse transcription polymerase chain reaction analysis of MSC-like cells derived from
control and MOSPD1-null ESC-derived MSC cells conﬁrming complete absence of Mospd1 transcripts. Abbreviation: CFU-F, colony form-
ing unit-ﬁbrobast.
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MOSPD1-null cells failed to proliferate when plated at a
deﬁned density (Fig. 3F). The lack of expression of Mospd1
mRNA transcripts was conﬁrmed in MOSPD1-null MSC-like
cells by qRT-PCR (Fig. 3G).
Our hypothesis that MOSPD1-null ESCs are deﬁcient in
their production of mesenchymal lineage cells is supported by
the observation that MOSPD1-null ESCs are also deﬁcient in
the production of osteoblasts (Fig. 4A). The ability of
MOSPD1-null ES cells to differentiate into cells that stained
positive with the histochemical stain Alizarin Red that marks
bone mineralization [15] was signiﬁcantly reduced compared
with control E14 ESCs (Fig. 4A; Supporting Information Fig.
S3). Adipocyte differentiation was also reduced in MOSPD1-
null cells as assessed by culturing EBs in the presence of RA,
IBMX, and insulin and staining with oil red O (Fig. 4B; Sup-
porting Information Fig. S3). We also observed a signiﬁcant
reduction in the production of hematopoietic progenitors
from MOSPD1-null ESCs compared with control cells (Fig. 4C).
Given that MSCs give rise to osteoblasts, adipocytes, and
chondrocytes, it is interesting that we did not observe any
signiﬁcant reduction in the production of chondrocytes
derived from MOSPD1-null ESCs compared with control E14
ESCs (Fig. 4D; Supporting Information Fig. S3). However, it is
noteworthy that the chondrocyte differentiation protocol is
relatively non-speciﬁc involving EB formation and then plating
of intact EBs on gelatin for 19 days in the presence of 15%
FCS with no added cytokines or morphogens. Interestingly,
there was no overt defect in the ability of intact MOSPD1-null
EBs to form cardiomyocytes which also involved a non-speciﬁc
differentiation assay without the addition of cytokines (Fig. 4E).
MOSPD1-null ESCs differentiated into spontaneously beating
cells at comparable frequency to wild type cells with approxi-
mately 85% of EBs forming beating cardiomyocytes from
both ESC lines (Fig. 4E). Furthermore, deﬁciency in Mospd1
expression did not affect the kinetics of cardiomyocyte
differentiation—beating regions appeared in the majority of
both control EBs and MOSPD1-null EBs by 10 days (data not
shown). To explore the cellular mechanism whereby Mospd1
functions we assessed the effects of cell density of the level of
expression of Mospd1. Control E14-derived MSC- like cells
grown at high density expressed signiﬁcantly higher levels of
the Mospd1 implying that cell-cell contact plays a role in the
control of Mospd1 expression (Fig. 4F).
Exogenous Expression of MOSPD1, but not MOSPD3,
Rescues Differentiation Deficiencies of MOSPD1-Null
ESCs
To conﬁrm that the deﬁciencies observed in MOSPD1-null
ESCs were indeed due to loss of the Mospd1 gene, MOSPD1-
null ESCs were transfected with either a CAG-Mospd1-IRES-
Figure 4. MOSPD1-null embryonic stem cells (ESCs) exhibit differentiation defects. The differentiation potential of control E14 ESCs and
MOSPD1-null ESCs was assessed in a range of assays (Supporting Information Figs. S2, S3). There was a signiﬁcant deﬁciency in the production
of osteoblasts (A), adipocytes (B), and hematopoietic progenitors (C) in two independently-derived MOSPD1-null ESCs (MOSPD1-null 1 and
MOSPD1-null 2) compared with control E14 ESCs. No signiﬁcant difference was observed in the production of chondrocytes (D) nor beating
cardiomyocytes (E) between control and MOSPD1-null cells. (F): Quantitative reverse transcription polymerase chain reaction analysis of
Mospd1 expression in MSC-like cells derived from control E14 ESCs grown at high and low density. Cells were plated at 2,500 cells per square
centimeter (low density) or 50,000 cells per square centimeter (high density) for 24 hours before harvesting and isolation of RNA.
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Puro or CAG-Mospd3-IRES-Puro plasmid. Expression of the
MOSPD1 and MOSPD3 proteins, in puromycin-resistant clones,
were conﬁrmed by Western blotting (Fig. 5A, 5B). We used
the most robust CFU-F and osteoblast differentiation assays in
our rescue experiments. The number of ﬁbroblast and osteo-
blast colonies at day 12 in MOSPD1-null cells transfected with
the Mospd1-expressing vector, was signiﬁcantly higher than
the number generated from parental MOSPD1-null cells (p <
0.05) with numbers being restored to levels observed in control
E14 ESCs (Fig. 5C, 5D). In contrast MOSPD1-null cells expressing
exogenous Mospd3 protein produced a comparable number of
ﬁbroblast and osteoblast colonies to the MOSPD1-null cells.
Thus, expression of exogenous MOSPD1 but not MOSPD3 pro-
tein rescued the deﬁciency observed in MOSPD1-null cells. These
data conﬁrm that MOSPD1 plays an important role in the differ-
entiation of these cell types and refutes the hypothesis that the
Mospd1 and Mospd3 genes are functionally redundant
Expression of Mospd1 in Perivascular MSC Ancestors
Given the apparent role of MOSPD1 in ESC-derived MSC pro-
liferation we analyzed the expression of this gene in MSC
native ancestors isolated from human adipose tissue. Natu-
ral forerunners of culture-deﬁned MSCs have been identiﬁed
as pericytes [19] and ASC [20]. We assessed the expression of
Figure 5. MOSPD1-null phenotype is rescued by exogenous expression of MOSPD1, but not MOSPD3. (A): Western blot of cell lysates
from control E14 embryonic stem cells (ESCs) (lane1), MOSPD1-null ESCs (lane 2), MOSPD1-null ESCs transfected with the control CAG
empty vector (lane 3) and two MOSPD1-null ESC clones that had been selected after transfection with the CAG-Mospd1 vector (lanes 4,
5). Blot was probed with an a-MOSPD1 antibody and a-GAPDH antibody as a loading control. (B): Western blot analysis of cell lysates
from COS cells transfected with the CAG-Mospd3 vector (lane1), untransfected E14 ESCs (lane 2) and one of the MOSPD1-null ESC
clones that had been selected after transfection with the CAG-Mospd3 vector (lane 3). Blot was probed with an a-MOSPD3 antibody
and the a-GAPDH antibody as a loading control. (C):The number of Alizarin Red-stained osteoblast colonies generated at day 12 from
control E14, MOSPD1-null and MOSPD1-null ESCs expressing exogenous MOSPD1 (MOSPD1R) or MOSPD3 (MOSPD3R). (D): The number
of colony forming unit-ﬁbrobast colonies generated from control E14, MOSPD1-null and MOSPD1-null ESCs expressing exogenous
MOSPD1 (MOSPD1R) or MOSPD3 (MOSPD3R). Abbreviation: CFU-F, colony forming unit-ﬁbrobast.
Table 1. RNA sequencing analysis (expressed as RPMK normalized fragment count numbers) to compare the expression level of Mospd1
in populations of freshly sorted and cultured ASCs and pericytes
Cell populations CD34 (ASC) CD146 (PERI) RGS5 (PERI) CD45 ALDH1A1 MOSPD1
Fresh sorted cells
ASC unsorted 2,820 1 1 1 1,051 21
ASC ALDH bright 1,763 1 37 43 1,461 11
ASC ALDH dim 2,388 1 14 45 648 1
Pericytes ALDH dim 23 698 6,526 45 168 1
Cultured cells
ASC ALDH bright 18 16 1 2 1 54
ASC ALDH dim 1 1 1 1 1 51
Pericytes ALDH dim 1 351 35 1 6 69
High levels of expression levels of CD34 and CD146/RGS5 conﬁrmed the phenotype of ASCs and pericytes respectively. CD146, RGS5 and
ALDH1A1 conﬁrmed the phenotype of sorted cell populations. (1 5 no detectable expression).
Abbreviations: ALDH, aldehyde dehydrogenase; ASC, advential cell; PERI, pericytes.
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a number of genes including Mospd1 by RNA sequencing in
freshly sorted pericytes (CD1461 CD452 CD312 CD342)
and ASCs (CD341CD1462CD452CD312) and then also in
these cells following culture for three passages. ASC and peri-
cytes were further subdivided based on Aldeﬂuor staining
intensity (ALDH-dim and ALDH-bright). Aldeﬂour is convert to
a highly ﬂuorescent product by isoforms of the enzyme ALDH
whose presence serves as a presumptive stem cell marker in
certain tissue speciﬁc and cancer stem cells. Cells staining
positive, or bright, for the presence of ALDH were gated in
comparison with a negative control population treated with
DEAB, an inhibitor of the ALDH enzyme (Supporting Informa-
tion Fig. S4).
RNA sequencing data conﬁrmed the identify of freshly
sorted cells; pericytes expressed high levels of CD146 com-
pared with ASCs; ASCs expressed higher levels of CD34 com-
pared with pericytes and ALDH bright ASCs expressed higher
levels of ALDH1A1 compared with ALDH-dim cells (Table 1).
There was a higher level of expression of Mospd1 in the
freshly sorted ALDH-bright compared with the ALDH-dim sup-
porting the hypothesis that Mospd1 is expressed in a more
stem-like population. The level of expression of Mospd1 was
signiﬁcantly increased in the proliferating MSCs that arise
from both pericytes and ASCs. In summary, the level of
Mospd1 mRNA expression correlated with the proliferative
status of the cells with virtually no expression in freshly
sorted pericytes, a slightly higher level in ASCs and a much
higher level of expression in MSCs that were cultured from
perivascular cells and ASC (Table 1).
DISCUSSION
Our study adds to the growing knowledge about MSP-
domain-containing proteins and has identiﬁed a role for
MOSPD1 in the differentiation and proliferation of mesenchy-
mal stem cells derived from ESC in vitro.
A previous study suggested that MOSPD1 plays a pivotal
role in the switch between epithelial and mesenchymal cells
[12]. siRNA knockdown of Mospd1 mRNA in an osteoblast cell
line resulted in increased expression of the epithelial cadherin
Cdh1, and down-regulation of its inhibitors, Snail1 and Snai2,
and the mesenchymal cadherin Cdh11 [12]. As Snai1 and Snai2
are essential for mesenchyme formation and for EMT [21, 22],
it was suggested that Mospd1 was a new player in this process
[12]. However, our studies using MOSPD1-null ESCs do not sup-
port the hypothesis that MOSPD1 controls the process of EMT
per se. We noted that expression of the EMT marker genes
Snai1, Snai2, and Cdh11 increased during ESC differentiation in
a comparable manner in both MOSPD1-null and control ESCs
indicating that Mospd1 does not play a role in their regulation.
The differentiation phenotype of MOSPD1-null ESCs suggests
that MOSPD1 is involved in the subsequent differentiation and
proliferation of MSCs. We noted that MOSPD1-null ESCs gener-
ated signiﬁcantly fewer colonies than control ESCs when plated
in conditions that favored the production of MSC-like cells
(CFU-F assay) and the production of osteoblasts and adipocytes
was also impaired.
MSCs are by deﬁnition culture-selected cells of which
native counterparts in the bone marrow and other organs have
long remained unknown. Having identiﬁed perivascular peri-
cytes and adventitial cells as the origin of the elusive MSCs
[23], we wished to determine whether these native MSC
ancestors already express Mospd1. Mospd1 mRNA was virtually
undetectable in pericytes and adventitial cells puriﬁed from
human adipose tissue but expression was dramatically aug-
mented in the progeny of these cells after culture, that is, in
their MSC descendants. An exception to this however was that
freshly sorted ALDH-bright adventitial cells already expressed
Mospd-1 at signiﬁcant levels which could suggest that some of
these cells are in a proliferative state in situ. These results fur-
ther support the hypothesis that MOSPD1 is involved in MSC
proliferation. Although the emergence in vivo of bona ﬁde
MSCs from pericytes has not been documented, it is accepted
that perivascular cells migrate away from blood vessels to par-
ticipate in tissue renewal and post-injury repair [24–28]. It will
be important to determine whether regenerative perivascular
cell mobilization and multiplication at sites of tissue injury is
also accompanied by Mospd1 expression.
We also observed a reduction in the number of hemato-
poietic progenitors that are generated within EBs derived
from differentiating ESCs and speculate that this could be
related to the deﬁciency in differentiation of mesenchymal
cells that are known to play a supportive role for hematopoi-
etic progenitors [20, 29]. Our ﬁndings that the expression of
Mospd1 is higher in cells that are plated at a high density
implies that-cell–cell contact could play a role in the regula-
tion of its expression.
The causal effect of MOSPD1 deﬁciency was conﬁrmed by
rescuing the differentiation defect by exogenous expression of
MOSPD1. We previously hypothesized a mechanism of func-
tional redundancy between the Mospd1 and Mospd3 genes
that might explain the loss of phenotype observed upon con-
tinued backcrossing of animals carrying a gene trap integra-
tion in the Mospd3 locus [11]. This study apparently refutes
this hypothesis as exogenous expression of MOSPD3 is not
able to rescue the differentiation deﬁciencies displayed by
MOSPD1-null cells. However, there could be alternative
explanations for the failure of MOSPD3 to rescue MOSPD1
deﬁciency; for example, if the function of MOSPD3 is depend-
ent on heterodimerization with MOSPD1.
CONCLUSION
In conclusion, the generation of MOSPD1-null ESCs lines pro-
vides a new tool to study the function of this poorly under-
stood gene family. In contrast to a previous report we show
that MOSPD1 is not essential for the transition of epithelial
cells to mesenchyme (EMT) but rather it is essential for the
subsequent proliferation and differentiation of mesenchymal
cells. These ﬁndings are supported by the expression proﬁle
of Mospd1 in subpopulations of MSCs and their precursors
isolated from human tissue.
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